{"url_path":"/sec/bcli/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062766-index.html","accession_number":"0001104659-26-062766","cik":"0001137883","ticker":"BCLI","issuer_name":"BRAINSTORM CELL THERAPEUTICS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062766-index.html","primary_entity_key":"0001137883","primary_entity_name":"BRAINSTORM CELL THERAPEUTICS INC."},"word_count":133,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial Condition.**\n\n \n\nOn May 15, 2026,\nBrainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The\nfull text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein\nby reference.\n\n \n\n*The information in\nthis Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of\nthe Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed\nincorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth\nby specific reference in such a filing.*"}